Awakn Life Sciences Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anthony Tennyson
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 301-217 Queen Street West Toronto ON Canada M5V 0R2
- IPO Date
- Aug 3, 2021
- Website
- awaknlifesciences.com
- Similar Companies
- Business
- Awakn Life Sciences Corp. (AWKNF) is a clinical-stage biotechnology company that researches, develops and delivers psychedelic-assisted therapeutics targeting substance use disorders and mental health conditions, including alcohol use disorder, post-traumatic stress disorder and related neuropsychiatric indications. The company offers a pipeline of proprietary product candidates such as AWKN-001, an investigational combination therapy of intravenous ketamine with structured relapse-prevention cognitive behavioral therapy for severe alcohol use disorder that is currently in a Phase 3 clinical trial across eight UK National Health Service sites co-funded by the UK Medical Research Council and National Institute for Health and Care Research; AWKN-002, a patent-pending sublingual or buccal esketamine formulation with manualized therapy for moderate to severe alcohol use disorder in Phase 2b planning in the United States; and AWKN-SDN-14, a preclinical series of serotonin, dopamine and noradrenaline receptor modulators aimed at PTSD with pro-social behavioral effects and improved safety over prior candidates. Awakn also maintains a proprietary library of preclinical drug candidates that have completed hit-to-lead progression with composition-of-matter patents filed across multiple chemical series; the company previously operated clinical delivery services and pursued partnerships for drug delivery technologies such as orally disintegrating tablets. Incorporated in 2018 and headquartered in Toronto, Canada, Awakn primarily targets patients in the United States, United Kingdom and European Union, where alcohol use disorder alone affects approximately 40 million adults and current treatments remain inadequate. In its most significant recent development, Awakn was fully acquired by Solvonis Therapeutics plc (LSE: SVNS) on May 27, 2025, pursuant to a plan of arrangement under British Columbia's Business Corporations Act, with all common shares, restricted share units and deferred share units exchanged for Solvonis ordinary shares at a ratio of 46.67-for-1, integrating Awakn's pipeline—including the renamed SVNS-001—into Solvonis' expanded platform for addiction and mental health therapeutics. Prior to the acquisition, Awakn expanded its Phase 3 MORE-KARE trial by opening four additional UK sites to reach seven active locations, secured an unsecured US$535,000 credit facility for working capital, settled debt through share issuances and advanced preclinical studies for its aminoindane program in collaboration with Concept Life Sciences and the University of Nottingham. The company, which listed on the Canadian Securities Exchange in 2021, no longer operates independently following the transaction.
Solvonis Therapeutics completes acquisition of Awakn Life Sciences
CSE Bulletin: Delist - Awakn Life Sciences Corp. (AWKN)
Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc
Awakn Life Sciences Announces Shareholder Approval of Arrangement
Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc
Solvonis Therapeutics lays out roadmap for Awakn Life Sciences acquisition
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Awakn Life Sciences Announces Credit Facility
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
Graft Polymer swoops for Awakn Life Sciences in £5m deal
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Graft Polymer CEO thrilled Awakn Life Sciences partnership progress
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder